Overview

Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia

Status:
Completed

Trial end date:
2007-03-01

Target enrollment:
0

Participant gender:
All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and combining drugs in different ways may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy in treating children who have very high risk acute lymphocytic leukemia.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Children's Oncology Group

Collaborator:

National Cancer Institute (NCI)

Treatments:

6-Mercaptopurine
Asparaginase
Cyclophosphamide
Cytarabine
Daunorubicin
Dexamethasone
Etoposide
Idarubicin
Leucovorin
Levoleucovorin
Mercaptopurine
Methotrexate
Prednisone
Vincristine

Criteria

DISEASE CHARACTERISTICS: Newly diagnosed B-cell precursor acute lymphocytic leukemia No L3
morphology Very poor prognosis CNS 3 (blasts and WBC greater than 5 microliters) OR Must
meet all of the following criteria: No simultaneous trisomy 4 and 10 DNA index no greater
than 1.16 (if FISH 4 and 10 unsatisfactory) No TEL-AML1 [t(12;21)] Meets at least 1 of the
following: Has MLL (11q23) and/or BCR-ABL [t(9;22)] WBC greater than 100,000/mm3 Age over
12 (boys) or 16 (girls) OR Boys Girls WBC 8 12 greater than 80,000/mm3 9 13 greater than
60,000/mm3 10 14 greater than 40,000/mm3 11 15 greater than 20,000/mm3 Concurrent
registration on stratum 6 of POG-9400 before 11/15/1999 OR Concurrent registration on
stratum 4 of POG-9900 after 11/15/1999 Concurrent registration on POG-9201, POG-9705, or
POG-9806 unless ineligible

PATIENT CHARACTERISTICS: Age: Children Performance status: Not specified Life expectancy:
Not specified Hematopoietic: See Disease Characteristics Hepatic: Not specified Renal: Not
specified

PRIOR CONCURRENT THERAPY: See Disease Characteristics